NPHC Stock - Nutra Pharma Corp.
Unlock GoAI Insights for NPHC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $438,274 | $97,735 | $51,897 | $104,393 | $130,596 |
| Gross Profit | $249,022 | $8,467 | $14,916 | $34,715 | $14,062 |
| Gross Margin | 56.8% | 8.7% | 28.7% | 33.3% | 10.8% |
| Operating Income | $-1,907,404 | $-1,920,115 | $-924,947 | $-1,168,104 | $-1,878,862 |
| Net Income | $8.18M | $-13,095,521 | $-769,184 | $-6,591,442 | $-3,884,695 |
| Net Margin | 1865.7% | -13399.0% | -1482.1% | -6314.1% | -2974.6% |
| EPS | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
Visit WebsiteEarnings History & Surprises
NPHCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 23, 2025 | — | — | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.00 | — | — |
Q3 2022 | Aug 22, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.00 | — | — |
Q4 2021 | Nov 10, 2021 | — | $0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.00 | — | — |
Q3 2020 | Sep 30, 2020 | — | $0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q1 2020 | Mar 31, 2020 | — | $0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.00 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.00 | — | — |
Q4 2018 | Nov 19, 2018 | — | $-0.00 | — | — |
Q3 2018 | Aug 17, 2018 | — | $-0.00 | — | — |
Q2 2018 | May 21, 2018 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about NPHC
What is NPHC's current stock price?
What is the analyst price target for NPHC?
What sector is Nutra Pharma Corp. in?
What is NPHC's market cap?
Does NPHC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NPHC for comparison